CORMEDIX INC (CRMD) Stock Price, Quote, News and Overview
NASDAQ:CRMD - Nasdaq - US21900C3088 - Common Stock - Currency: USD
CRMD Quote, Performance and Key Statistics
12.5
-2.46 (-16.44%)
The current stock price of CRMD is 12.5 USD. In the past month the price increased by 2.29%. In the past year, price increased by 188.68%.
CRMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.36 | 734.92B | ||
| JNJ | JOHNSON & JOHNSON | 15.17 | 366.71B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.57 | 304.42B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.44 | 237.03B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.87 | 216.57B | ||
| MRK | MERCK & CO. INC. | 10.15 | 198.62B | ||
| PFE | PFIZER INC | 7.54 | 137.53B | ||
| SNY | SANOFI-ADR | 10.49 | 116.45B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.31 | 94.33B | ||
| GSK | GSK PLC-SPON ADR | 8.54 | 78.19B | ||
| ZTS | ZOETIS INC | 25.94 | 69.53B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 62.92 | 47.17B |
Related stock screener links
About CRMD
Company Profile
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 64 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Company Info
CORMEDIX INC
300 Connell Drive, Suite 4200
Berkeley Heights NEW JERSEY 07922 US
CEO: Khoso Baluch
Employees: 65
Phone: 19085179500
CORMEDIX INC / CRMD FAQ
What is the stock price of CORMEDIX INC today?
The current stock price of CRMD is 12.5 USD. The price decreased by -16.44% in the last trading session.
What is the ticker symbol for CORMEDIX INC stock?
The exchange symbol of CORMEDIX INC is CRMD and it is listed on the Nasdaq exchange.
On which exchange is CRMD stock listed?
CRMD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CORMEDIX INC stock?
12 analysts have analysed CRMD and the average price target is 16.73 USD. This implies a price increase of 33.82% is expected in the next year compared to the current price of 12.5. Check the CORMEDIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CORMEDIX INC worth?
CORMEDIX INC (CRMD) has a market capitalization of 847.75M USD. This makes CRMD a Small Cap stock.
How many employees does CORMEDIX INC have?
CORMEDIX INC (CRMD) currently has 65 employees.
What are the support and resistance levels for CORMEDIX INC (CRMD) stock?
CORMEDIX INC (CRMD) has a support level at 6.58. Check the full technical report for a detailed analysis of CRMD support and resistance levels.
Is CORMEDIX INC (CRMD) expected to grow?
The Revenue of CORMEDIX INC (CRMD) is expected to grow by 264.58% in the next year. Check the estimates tab for more information on the CRMD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CORMEDIX INC (CRMD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRMD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRMD, evaluating the profitability, health, valuation and growth aspects
- CORMEDIX INC (CRMD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CORMEDIX INC (CRMD) Sales and EPS estimates to see what analysts future expectations are.
- CORMEDIX INC (CRMD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CORMEDIX INC (CRMD) Insider and Institutional Ownership to learn about the owners and their transactions.
- CORMEDIX INC (CRMD) Stock Chart to make your own analysis
- CORMEDIX INC (CRMD) Latest news and press-releases to stay up to date.
Does CORMEDIX INC (CRMD) stock pay dividends?
CRMD does not pay a dividend.
When does CORMEDIX INC (CRMD) report earnings?
CORMEDIX INC (CRMD) will report earnings on 2025-08-12, before the market open.
What is the Price/Earnings (PE) ratio of CORMEDIX INC (CRMD)?
The PE ratio for CORMEDIX INC (CRMD) is 56.82. This is based on the reported non-GAAP earnings per share of 0.22 and the current share price of 12.5 USD. Check the full fundamental report for a full analysis of the valuation metrics for CRMD.
What is the Short Interest ratio of CORMEDIX INC (CRMD) stock?
The outstanding short interest for CORMEDIX INC (CRMD) is 12.73% of its float. Check the ownership tab for more information on the CRMD short interest.
CRMD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CRMD. When comparing the yearly performance of all stocks, CRMD is one of the better performing stocks in the market, outperforming 98.27% of all stocks.
CRMD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CRMD. CRMD has an excellent financial health rating, but there are some minor concerns on its profitability.
CRMD Financial Highlights
Over the last trailing twelve months CRMD reported a non-GAAP Earnings per Share(EPS) of 0.22. The EPS increased by 123.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.81% | ||
| ROA | 11.49% | ||
| ROE | 14.95% | ||
| Debt/Equity | 0 |
CRMD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CRMD. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 346.76% and a revenue growth 264.58% for CRMD